EP
ALDX icon

Essential Partners’s Aldeyra Therapeutics ALDX Stock Holding History

Essential Partners’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.41K Sell
2,070
-33,823
-94% -$58.1K ﹤0.01% 1604
2026
Q1 		$60.7K Buy
35,893
+705
+2% +$3.09K 0.02% 555
2025
Q4 		$182K Sell
35,188
-26
-0.1% -$134 0.06% 331
2025
Q3 		$184K Buy
35,214
+1,037
+3% +$5.41K 0.06% 335
2025
Q2 		$131K Buy
+34,177
New +$88.4K 0.05% 327

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Essential Partners's ALDX Position: Q2 2026 in Review

Essential Partners reduced its Aldeyra Therapeutics (ALDX) stake by 94% in Q2 2026, selling an estimated $58.1K and leaving 2,070 shares worth $4.41K. The position accounts for ﹤0.01% of the portfolio, ranked #1604.

Essential Partners first reported a position in ALDX in Q2 2025 and has held it in 5 quarters since. The position peaked at $184K in Q3 2025. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Essential Partners held 2,070 shares of Aldeyra Therapeutics worth $4.41K as of Q2 2026.
  • Essential Partners sold 33,823 Aldeyra Therapeutics shares in Q2 2026, an estimated $58.1K.
  • Aldeyra Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1604 holding.
  • Essential Partners first reported a position in Aldeyra Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Essential Partners's Aldeyra Therapeutics position peaked at $184K in Q3 2025.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.